Management of Low-Grade Myoepithelial Carcinoma of the Head and Neck
Complete surgical resection with negative margins (R0 resection) is the primary treatment for low-grade myoepithelial carcinoma of the head and neck, with adjuvant radiotherapy reserved for patients with adverse risk features to improve locoregional control. 1
Primary Treatment Approach
Surgical Management
- Wide surgical excision is the cornerstone of therapy and must be performed with high technical standards at the initial operation. 2, 3
- R0 resection is associated with significantly better progression-free survival (PFS) and overall survival (OS) compared to incomplete resection 1
- The requirements for the first surgery are particularly high, as inadequate initial resection leads to high recurrence rates 2, 4
- For major salivary gland tumors, complete gland resection with appropriate margins should be performed 2
Role of Adjuvant Radiotherapy
- Adjuvant radiation should be considered for patients with adverse risk features to reduce locoregional recurrence. 1
- Adjuvant radiation has been demonstrated to reduce locoregional recurrence rates in myoepithelial carcinoma 1
- Specific indications for adjuvant radiotherapy include:
Important caveat: While adjuvant radiation improves locoregional control, it does not appear to improve overall survival in multivariate analysis, though this may reflect selection bias toward higher-risk patients receiving adjuvant therapy 1
Surveillance Strategy
Imaging Protocol
- Post-treatment imaging should be obtained at 3 months, then yearly for 12-24 months, with continued yearly surveillance thereafter given the indolent biology of low-grade tumors. 5
- MRI with contrast is preferred for head and neck surveillance as it offers better soft-tissue characterization and is more sensitive for detecting perineural spread 5
- Annual chest CT (not chest X-ray) should be performed for at least 2 years and can be extended beyond 5 years, as late pulmonary metastases are common in salivary gland malignancies. 5
Clinical Follow-up
- Close monitoring is essential as myoepithelial carcinoma has high rates of local recurrence (28.8-41%) and distant metastasis (13.6-22%) 2, 6
- Younger patients (≤60 years) are at higher risk for distant metastasis and require particularly vigilant surveillance 6
Management of Recurrent or Metastatic Disease
Oligometastatic Disease
- For low-grade tumors with limited metastases (≤5 lesions), local ablative treatments such as metastasectomy or stereotactic body radiation therapy (SBRT) should be offered to delay disease progression. 5
- This approach is particularly appropriate given the indolent biology of low-grade myoepithelial carcinoma 5
- Complete surgical resection is preferred when technically feasible 5
- SBRT is an option when surgery is contraindicated or technically difficult 5
Systemic Therapy Considerations
- Chemotherapy has not been shown to be particularly effective for myoepithelial carcinoma 4, 7
- For unresectable recurrent disease, concurrent chemoradiotherapy may be considered, though evidence is limited to case reports 3, 8
Prognostic Factors
Key adverse prognostic factors include:
- Major salivary gland location (versus minor salivary glands) 2
- Advanced clinical stage (Stage III-IV) 2
- Tumor size >5 cm 1
- Mitotic index >10/10 high power field 1
- Clinically positive neck lymph nodes 6
Expected outcomes: The 5-year survival rate for myoepithelial carcinoma ranges from 62-71%, with 1-year and 3-year survival rates of 92% and 73%, respectively 2, 6
Critical Pitfalls to Avoid
- Do not rely on chest X-ray for surveillance—it lacks adequate sensitivity for detecting pulmonary metastases 5
- Do not perform inadequate initial surgery, as this is the most important modifiable risk factor for recurrence 2, 4
- Do not discontinue surveillance at 5 years, as late metastases are characteristic of salivary gland malignancies 5
- Recognize that despite the "low-grade" designation, these tumors have significant metastatic potential and require aggressive initial management 2, 6